Selecta Biosciences, Inc. (SELB)
(Delayed Data from NSDQ)
$2.35 USD
+0.23 (10.85%)
Updated May 3, 2019 04:00 PM ET
After-Market: $2.36 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.35 USD
+0.23 (10.85%)
Updated May 3, 2019 04:00 PM ET
After-Market: $2.36 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Selecta's (SELB) Gene Therapy Gets Orphan Drug Tag From FDA
by Zacks Equity Research
The FDA bestows an orphan drug status on Selecta's (SELB) gene therapy candidate MMA-101 for the treatment of isolated methylmalonic acidemia. The candidate already has a Rare Pediatric Disease tag.
Selecta's (SELB) Q3 Loss Narrower-Than Expected, Revenues Beat
by Zacks Equity Research
Selecta (SELB) beat estimates for both earnings and revenues in the third quarter of 2020.
What's in Store for Selecta (SELB) This Earnings Season?
by Zacks Equity Research
In absence of any marketed product, investor focus will be on Selecta's (SELB) efforts to develop its lead pipeline candidate SEL-212 during the third-quarter conference call.
Selecta's (SELB) Gene Therapy Gets Rare Pediatric Disease Tag
by Zacks Equity Research
The FDA bestows a Rare Pediatric Disease status on Selecta's (SELB) gene therapy candidate MMA-101, which is being developed for the treatment of isolated methylmalonic acidemia.
Selecta Biosciences, Inc. (SELB) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Selecta Biosciences, Inc. (SELB) delivered earnings and revenue surprises of -153.13% and -100.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Selecta Biosciences (SELB) Q2 Earnings & Sales Miss Estimates
by Zacks Equity Research
Selecta Biosciences (SELB) miss estimates for earnings and revenues in the second quarter of 2020.
What Awaits Selecta Biosciences (SELB) This Earnings Season?
by Zacks Equity Research
In the absence of any marketed drugs, investor focus is likely to be on Selecta Biosciences' (SELB) lead pipeline candidate, SEL-212 on the second-quarter conference call.
Is Selecta Biosciences (SELB) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (SELB) Outperforming Other Medical Stocks This Year?
Selecta Biosciences (SELB) in Focus: Stock Moves 7.4% Higher
by Zacks Equity Research
Selecta Biosciences (SELB) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Is Selecta Biosciences (SELB) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (SELB) Outperforming Other Medical Stocks This Year?
Is Selecta (SELB) Stock a Solid Choice Right Now?
by Zacks Equity Research
Selecta (SELB) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Selecta Biosciences Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Selecta Biosciences has been struggling lately, but the selling pressure may be coming to an end soon.
Will Selecta Biosciences Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Selecta Biosciences.
Selecta Biosciences Enters Oversold Territory
by Zacks Equity Research
Selecta Biosciences, Inc. (SELB) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Selecta Biosciences (SELB) In Focus: Stock Moves 6.5% Higher
by Zacks Equity Research
Selecta Biosciences (SELB) moved big last session, as its shares jumped over 6% on the day.
Selecta Biosciences (SELB) Enters Oversold Territory
by Zacks Equity Research
Selecta Biosciences, Inc. (SELB) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock
Selecta Biosciences (SELB): Strong Industry, Solid Earnings Estimate Revisions
by Zacks Equity Research
Selecta Biosciences (SELB) is seeing solid earnings estimate revision activity, and is a great company from a Zacks Industry Rank perspective.